Deals
Amgen Is Said to Agree to Buy Horizon at $26 Billion Value
- Amgen agrees to pay around $116.5 for each Horizon share
- Sanofi, Johnson & Johnson both walked away from discussions
This article is for subscribers only.
Amgen Inc. has agreed to buy Horizon Therapeutics Plc at a valuation of about $26 billion in what would be its biggest-ever acquisition, according to a person familiar with the matter.
The US biotechnology giant offered around $116.5 for each Horizon share, said the person, who asked not to be identified as the information is private. The offer price is at a around 20% premium to Horizon’s closing price of $97.29 on Friday.